Igc pharma reports igc-m3's in vitro efficacy against alzheimer's - targeting key drivers of disease progression

- new hope in alzheimer's: igc-m3 targets the disease on four fronts, showing promise in cellular models - potomac, md / access newswire / august 5, 2025 / igc pharma, inc. (nyse american:igc) ("igc" or the "company"), a clinical-stage pharmaceutical company leveraging ai to develop innovative treatments for alzheimer's and metabolic disorders, today announced encouraging preclinical data on its investigational molecule "igc-m3". the invitro results demonstrates that igc-m3 may offer disease-modifying potential by targeting multiple biological mechanisms central to alzheimer's pathology, including amyloid aggregation, oxidative stress, mitochondrial dysfunction, and neuroinflammation.
IGC Ratings Summary
IGC Quant Ranking